Carolyn J Albert Selected Research

Plasmalogens

1/2022	Plasmalogen Loss in Sepsis and SARS-CoV-2 Infection.
12/2021	Identification of novel neutrophil very long chain plasmalogen molecular species and their myeloperoxidase mediated oxidation products in human sepsis.
7/2008	2-Chlorohexadecanal and 2-chlorohexadecanoic acid induce COX-2 expression in human coronary artery endothelial cells.
6/2006	Metabolism of myeloperoxidase-derived 2-chlorohexadecanal.
9/2003	Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein.
3/2003	Eosinophil peroxidase-derived reactive brominating species target the vinyl ether bond of plasmalogens generating a novel chemoattractant, alpha-bromo fatty aldehyde.
2/2002	Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: production of the chemoattractant, 2-chlorohexadecanal.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carolyn J Albert Research Topics

Disease

7	Inflammation (Inflammations) 07/2020 - 02/2002
7	Atherosclerosis 01/2019 - 09/2003
3	Sepsis (Septicemia) 01/2022 - 12/2017
3	Neoplasms (Cancer) 01/2021 - 11/2018
3	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2018
3	Atherosclerotic Plaque (Atheroma) 08/2013 - 06/2006
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2022 - 12/2017
2	Acute Lung Injury 01/2021 - 09/2019
2	Lung Injury 01/2021 - 09/2019
2	Obesity 01/2021 - 01/2013
2	Hemolysis 01/2021 - 09/2019
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2014 - 09/2009
1	Infections 01/2022
1	COVID-19 01/2022
1	Acute Chest Syndrome 01/2021
1	Respiratory Acidosis 01/2021
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2021
1	Tularemia 07/2020
1	Pulmonary Edema 09/2019
1	Progeria (Hutchinson Gilford Syndrome) 01/2019
1	Triple Negative Breast Neoplasms 11/2018
1	Non-alcoholic Fatty Liver Disease 10/2014
1	Weight Gain 10/2014
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2014
1	Cholestasis 09/2012
1	Myocardial Infarction 06/2005
1	Infarction (Infarctions) 06/2005
1	Asthma (Bronchial Asthma) 03/2003

Drug/Important Bio-Agent (IBA)

8	Peroxidase (Myeloperoxidase)IBA 12/2021 - 09/2003
7	PlasmalogensIBA 01/2022 - 02/2002
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2009
4	LipidsIBA 01/2022 - 09/2009
3	AldehydesIBA 06/2006 - 02/2002
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 11/2013
2	Heme (Haem)IBA 01/2021 - 09/2019
2	oxidized low density lipoproteinIBA 01/2021 - 09/2003
2	ChlorineIBA 01/2021 - 01/2016
2	Lipoproteins (Lipoprotein)IBA 01/2021 - 08/2013
2	CholesterolIBA 11/2018 - 10/2014
2	AcidsIBA 12/2017 - 09/2014
2	Phosphotransferases (Kinase)IBA 11/2013 - 08/2013
2	2-chlorohexadecanalIBA 07/2008 - 06/2006
1	CytokinesIBA 01/2022
1	1,2-Dipalmitoylphosphatidylcholine (Dipalmitoylphosphatidylcholine)IBA 01/2022
1	K-18 conjugate (K18)IBA 01/2022
1	phosphatidal ethanolaminesIBA 12/2021
1	Group IV Phospholipases A2IBA 01/2021
1	HemopexinIBA 01/2021
1	Stearic AcidsIBA 01/2021
1	Heme Oxygenase-1IBA 01/2021
1	Lipoxygenase (Lipoxygenase-1)IBA 07/2020
1	5-hydroxy-6,8,11,14-eicosatetraenoic acidIBA 07/2020
1	VaccinesIBA 07/2020
1	Biological ProductsIBA 07/2020
1	Blood Proteins (Serum Proteins)IBA 09/2019
1	PhosgeneIBA 09/2019
1	Triglycerides (Triacylglycerol)IBA 10/2014
1	Glucose (Dextrose)FDA LinkGeneric 10/2014
1	2-acylglycerol O-acyltransferaseIBA 10/2014
1	Insulin (Novolin)FDA Link 10/2014
1	Nonesterified Fatty Acids (NEFA)IBA 10/2014
1	DiglyceridesIBA 10/2014
1	CalciumIBA 09/2014
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 08/2013
1	Lipase (Acid Lipase)FDA Link 08/2013
1	TropomyosinIBA 08/2013
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2012
1	fatty aldehydeIBA 07/2008
1	salicylhydroxamic acid (SHAM)IBA 06/2005
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 09/2003
1	Oxidants (Oxidizing Agents)IBA 03/2003
1	vinyl ether (divinyl ether)IBA 02/2002

Therapy/Procedure

2	Immunotherapy 01/2021 - 01/2021
2	Therapeutics 01/2021 - 01/2019
1	bitter melon extract 11/2018
1	Intranasal Administration 01/2016